Oncology Practice Management

Featured Articles

Do No Financial Harm: How to Improve Cost Transparency in Cancer Care

We’ve heard the figures before: the price of cancer drugs has risen by orders of magnitude per month over the past decades. In addition to cancer treatment becoming more expensive, insurance design and drug formularies have changed, resulting in a greater financial burden for patients.

Read Article
One Oncologist’s Firsthand Experience with Serious Illness: What Your Patients Want

There’s really only one way to identify how patients are coping with serious illness: by asking them, according to Thomas J. Smith, MD, FACP, Director of Palliative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD.

Read Article
Harnessing the Power of Data Collection and Coordination in Oncology Practice

Business intelligence is the process of collecting data from disparate systems—internal and external—and turning it into information that is meaningful and actionable toward achieving strategic goals.

Read Article
What Does an Ideal Navigation Program Look Like?

Katherine Sharpe, SVP ACS explains how to evaluate what makes an ideal navigation program.

Read Article

Top Trending Articles

1.

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

By Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP; Aung Naing, MD, FACP

2.

Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns

By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

3.

Predicting High-Risk Disease Using Progression of Disease in 24 Months (POD24) and the Key Role of Repeat Biopsy to Exclude the Diagnosis of Transformation to a High-Grade Lymphoma in Patients with Relapsed Follicular Lymphoma

By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

Interview with the Innovators

In The News

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak

FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

By Yvette Florio Lane

View More Articles

Highlights From the Latest Issue: November 2022, Vol 12, No 11

November 2022, Vol 12, No 11

Overcoming Challenges in the Treatment of Primary Brain Tumors

By William King

The Cures Act Information Blocking Rule: Impact on Data Access, Interoperability, and Security

By Kem Tolliver, CMOM, CPC, CMPE

Implementing a Transportation Hub: A Holistic Approach to a Systemic Problem

Early Detection Blood Test May Change Cancer Screening Paradigms

By Patricia Stewart

Practice Management

The Cures Act Information Blocking Rule: Impact on Data Access, Interoperability, and Security

By Kem Tolliver, CMOM, CPC, CMPE

The Importance of Skills Gap Assessments and Training

By Shawntea (Taya) Moheiser, MBA, CMPE, CMOM

The Patient Experience: How to Plan for Success

By Jason Lockard, CMOM-HEM/ONC; Bettinna Signori, CMOM-HEM/ONC

Refueling When Your Emotional Tank Is Empty: Addressing Healthcare Worker Burnout

By Jan Hailey, MHL, CMC, CMCO, CMIS, CMOM

View More Articles

Reimbursement

Dispelling Misconceptions About HCC Coding

By Karyn M. Dyehouse, MD

Medications Used for the Treatment of Bladder Cancer and Associated ICD-10 Coding

By Kristin A. Esposito, CPhT

Medications Used for the Treatment of Lung Cancer and Associated ICD-10 Coding

By Kristin A. Esposito, CPhT

How Your Oncology Practice Can Thrive with MACRA: Get Ready for the Quality Payment Program

By Meg Barbor, MPH

View More Articles

Immunotherapy News

Therapeutic Cancer Vaccines: The Next Frontier

By Cecile Miller, MSN, CRNP; Faith A. Mutale, MSN, CRNP

Adding 2 Immunotherapies to Cabozantinib Extends Survival in Advanced Liver Cancer

By Wayne Kuznar

Atezolizumab-Bevacizumab Combo Improves Survival and Quality of Life in Unresectable Liver Cancer

By Wayne Kuznar

View More Articles

Reader Poll

New Videos

$Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans$

Relapsed or Refractory FL: Best Practices for Active Surveillance & Reinforcement of Management Plans

By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

Interview with the Innovators

Updates on 1L Maintenance Therapy with PARP Inhibitors for Advanced Ovarian Cancer

Updates on 1L Maintenance Therapy with PARP Inhibitors for Advanced Ovarian Cancer

By David O’Malley, MD

Rapid Reactions

Predicting High-Risk Disease Using Progression of Disease in 24 Months (POD24) and the Key Role of Repeat Biopsy to Exclude the Diagnosis of Transformation to a High-Grade Lymphoma in Patients with Relapsed Follicular Lymphoma

Predicting High-Risk Disease Using Progression of Disease in 24 Months (POD24) and the Key Role of Repeat Biopsy to Exclude the Diagnosis of Transformation to a High-Grade Lymphoma in Patients with Relapsed Follicular Lymphoma

By Tycel J. Phillips, MD; Peg Rummel, MHA, RN, OCN, NE-BC; Andrew D. Zelenetz, MD, PhD

Interview with the Innovators

View More Videos

Subscribe Today!

To sign up for our free e-Newsletter or print publications, please enter your contact information below.

I'd like to receive:

OPM e-Newsletter

OPM print publication

I have reviewed and consent to the terms of OPM's Privacy Policy, and OPM has my permission to retain my information in its database, and to forward pertinent communications to me.